Oncology | Approved Drugs in UNITED KINGDOM

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Imfinzi Approved in the EU for the Treatment of Extensive-Stage Small Cell Lung Cancer

Lead Product(s): Durvalumab,Tremelimumab,Carboplatin

Therapeutic Area: Oncology Product Name: Imfinzi

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 01, 2020

Details:

Imfinzi is the only PD-1/PD-L1 immunotherapy to demonstrate a significant survival benefit and improved response rate in combination with a choice of chemotherapies.

GlaxoSmithKline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

European Commission Approves Glaxo Smith Kline's Blenrep for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Lead Product(s): Belantamab mafodotin

Therapeutic Area: Oncology Product Name: Blenrep

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 26, 2020

Details:

BLENREP is a first-in-class humanised anti-BCMA (B-cell maturation antigen) treatment for these patients whose disease has progressed despite the current standard of care.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Imfinzi Approved in Japan for the Treatment of Extensive-Stage Small Cell Lung Cancer

Lead Product(s): Durvalumab,Tremelimumab,Carboplatin

Therapeutic Area: Oncology Product Name: Imfinzi

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 21, 2020

Details:

The approval was based on positive results from the Phase III CASPIAN trial, showing Imfinzi plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival vs chemotherapy alone.

GlaxoSmithKline

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Lead Product(s): Belantamab mafodotin

Therapeutic Area: Oncology Product Name: Blenrep

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 06, 2020

Details:

BLENREP is a first-in-class anti-BCMA (B-cell maturation antigen) therapy for patients whose disease has progressed despite prior treatment with an immunomodulatory agent, proteasome inhibitor and anti-CD38 antibody.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

EU Nod for Lynparza in Pancreatic Cancer

Lead Product(s): Olaparib

Therapeutic Area: Oncology Product Name: Lynparza

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 08, 2020

Details:

The approval was based on data from the Phase III POLO trial, published in The New England Journal of Medicine, in which Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1

Lead Product(s): Selumetinib

Therapeutic Area: Oncology Product Name: Koselugo

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

In the SPRINT trial, selumetinib was shown to reduce the size of these tumours in children. Phase I/II SPRINT Stratum 1 trial showed an overall response rate of 66% in paediatric patients with NF1 PN when treated with selumetinib as a twice-daily oral monotherapy.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials

Lead Product(s): Acalabrutinib

Therapeutic Area: Oncology Product Name: Calquence

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 11, 2020

Details:

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Lead Product(s): Olaparib,Bevacizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 08, 2020

Details:

U.S. FDA has approved LYNPARZA in combination with bevacizumab as a first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Porton Biopharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

Porton Biopharma Limited Licenses Erwinase® to Clinigen

Lead Product(s): Asparaginase

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Clinigen Group

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 16, 2020

Details:

Under the terms of the agreement, Clinigen will distribute Erwinase®/ Erwinaze®, the Porton's life-saving treatment for acute lymphoblastic leukaemia.

AstraZeneca PLC

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

BIO IMPACT

Participation Not Confirmed

Update your events

FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease

Lead Product(s): Selumetinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 13, 2020

Details:

The approval was based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase II SPRINT Stratum 1 trial.

Find

Find Approved Oncology Drugs in Clinical Development in UNITED KINGDOM

United Kingdom

Product Type

Companies

AstraZeneca PLC

Imfinzi Approved in the EU for the Treatment of Extensive-Stage Small Cell Lung Cancer

GlaxoSmithKline

European Commission Approves Glaxo Smith Kline's Blenrep for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

AstraZeneca PLC

Imfinzi Approved in Japan for the Treatment of Extensive-Stage Small Cell Lung Cancer

GlaxoSmithKline

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

AstraZeneca PLC

EU Nod for Lynparza in Pancreatic Cancer

AstraZeneca PLC

Selumetinib Granted Orphan Drug Designation in Japan for Neurofibromatosis Type 1

AstraZeneca PLC

Calquence Showed Long-Term Efficacy and Tolerability for Patients with Chronic Lymphocytic Leukaemia in Two Trials

AstraZeneca PLC

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

Porton Biopharma

Porton Biopharma Limited Licenses Erwinase® to Clinigen

AstraZeneca PLC

FDA Approves First Therapy for Children with Debilitating and Disfiguring Rare Disease